Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza G1 mHA
- Development stage
- Approved
- Lead developer
- Janssen Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
INFLUENZA G1 mHA is an experimental universal influenza vaccine candidate designed to provide broad and durable protection against group 1 influenza A viruses. It is a recombinant subunit vaccine based on a stabilized trimeric hemagglutinin (HA) stem protein derived from the H1 subtype, known as the "mini-hemagglutinin" or "mHA." The vaccine aims to elicit broadly neutralizing antibodies targeting conserved regions of the HA stem, potentially offering cross-protection against diverse seasonal and pandemic strains. Clinical studies have evaluated its safety and immunogenicity in healthy adults using various adjuvant formulations such as aluminum hydroxide (Al(OH)3). The developer is Janssen Vaccines & Prevention BV[1][3][4].
- Other names
- H1 stem antigenH-1 stem antigenH 1 stem antigenmini-hemagglutinin stem-derived protein vaccine antigen
02
Targets
Group 1 HA stalk (Influenza A hemagglutinin stalk domain, group 1)
Beyond the preview
Go deeper on Influenza G1 mHA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Influenza G1 mHA.